|
|
|
Volumn 40, Issue 12, 2001, Pages 1416-
|
|
How many patients are eligible for anti-TNF therapy in the UK? [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL RESPONSE MODIFIER;
ETANERCEPT;
INFLIXIMAB;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
TUMOR NECROSIS FACTOR ANTIBODY;
ANAMNESIS;
CLINICAL STUDY;
CONTROLLED STUDY;
DATA ANALYSIS;
DISEASE ACTIVITY;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG USE;
HOSPITAL DEPARTMENT;
HUMAN;
INFECTION;
INFORMATION PROCESSING;
LETTER;
MAJOR CLINICAL STUDY;
MALIGNANT NEOPLASTIC DISEASE;
PATIENT CARE;
POPULATION;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SCORING SYSTEM;
TREATMENT PLANNING;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
ELIGIBILITY DETERMINATION;
GREAT BRITAIN;
HUMANS;
IMMUNOGLOBULIN G;
INCIDENCE;
PREVALENCE;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0035681427
PISSN: 14620324
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (9)
|
|
References (0)
|
